Pivoted FASN inhibitor carries Phase 3 acne data and $258M into a US trial — success or failure hinges on replicating Ascletis results in a Western population

Sagimet is a clinical-stage biopharmaceutical company developing a targeted acne drug that is not yet approved, pivoting its focus after promising Phase 3 results from an international partner suggested the treatment could work in Western patients.

Sagimet pivoted from MASH to dermatology after its licensed partner Ascletis demonstrated denifanstat met all primary and secondary endpoints in a 480-patient Phase 3 acne trial, with a 33.2% vs 14.6% placebo treatment success rate. The thesis resolves on whether the US Phase 3 replicates that efficacy, since the entire registrational case rests on a single domestically-run trial with no prior US data. Generalizability across geographies is the central approval-path risk, and a $175M dilutive raise completed at $6.00 per share has already reset the shareholder base.